Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Looks like a Massive Squeeze is in-bound:
Scilex Holding Company Announces that Sorrento Therapeutics, Inc.’s Bankruptcy Court Issues Temporary Restraining Order Against Brokerage Firms and Suspends Short-Sales of Dividended Scilex Stock
PALO ALTO, Calif., June 15, 2023 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex”), a majority-owned subsidiary of Sorrento Therapeutics, Inc. (OTC: SRNEQ), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, announced that, in connection with Sorrento Therapeutics, Inc.’s ongoing chapter 11 case, the U.S. Bankruptcy Court for the Southern District of Texas (the “Bankruptcy Court”) has entered a temporary restraining order suspending short-sales of common stock of Scilex Holding Company (Nasdaq: SCLX, “Scilex”) that Sorrento distributed to its stockholders on or around January 19, 2023 (the “Dividended Scilex Stock”).??
In addition, the Bankruptcy Court ordered certain brokerage firms to provide an accounting of all profits received from naked short-selling of Dividended Scilex Stock and Scilex common stock, including all interest charged to short-sellers, no later than five business days after entry of the order.
The Bankruptcy Court’s temporary restraining order grants a request by the Official Committee of Equity Security Holders in Sorrento’s chapter 11 case, who had asked for the relief. The Official Committee of Equity Security Holders was appointed in the case to act as a fiduciary for, and represent the interests of, all Sorrento stockholders.
The Bankruptcy Court will conduct a hearing to consider the committee’s related request for a preliminary injunction on such issues on June 27, 2023 at 9:30 a.m. (prevailing Central Time) in Courtroom 400, 515 Rusk Street, Houston, Texas.
I suspect once the brokerages comply with the latest court order to close out all short positions or pay the $1/share short after the 5 day compliance period for every share not covered, the restricted shares will be unrestricted. BUT only after all the short positions both naked and common have been closed out and paid for. Over 10 million short with only 3 million in the float. Hummmmm, you do the math!
NO! The restriction will remain until 9/1/23.
Not having a value on your sclx divi shares would be like you transfering cash in to your account and the brokerage not have it show up in your account and telling you, you will have to wait until we are done using your cash.
"Sorrento Therapeutics, Inc.'s Bankruptcy Court Orders Brokerage Firms to Credit Dividended Scilex Stock to Customers' Accounts and Sorrento Advises Holders of Dividended Scilex Stock to Contact Brokerage Firms to Deliver the Stock to Individual Accounts"
https://finance.yahoo.com/news/sorrento-therapeutics-inc-bankruptcy-court-190000312.html
I wonder if this means that once the dividend shares are distributed to our accounts that we can sell immediately, before the September 1 restriction date?
What is up with this, was it a shirt squeeze, pump and dump? So many of us have these dividend shares but was locked up , it’s a joke.
https://www.otcmarkets.com/filing/conv_pdf?id=16588662&guid=5lu-kpannBpCJth
Item 8.01. Other Events.
As previously disclosed, the Company’s majority stockholder, Sorrento Therapeutics, Inc. (“Sorrento”) and its wholly-owned direct subsidiary, Scintilla Pharmaceuticals, Inc. (together with Sorrento, the “Debtors”), commenced voluntary proceedings under Chapter 11 of the United States Bankruptcy Code (the “Bankruptcy Code,” and such cases, the “Chapter 11 Cases”) in the United States Bankruptcy Court for the Southern District of Texas (the “Bankruptcy Court”).
As previously disclosed, on or around January 19, 2023, Sorrento distributed shares of the Company’s common stock to Sorrento’s stockholders (the “Distributed Stock”), which were restricted from being further transferred until May 11, 2023 (the “Lock-up”) as reflected in a restrictive legend.
On April 24, 2023, the Official Committee of Unsecured Creditors in the Chapter 11 Cases filed the Official Committee of Unsecured Creditors’ Emergency Motion to Extend the Application of the Automatic Stay to Continue the Restricted Trading Period for Shares of Scilex Stock Distributed to the Debtors’ Shareholders (the “Motion”), seeking the Bankruptcy Court’s extension of the application of the automatic stay to continue the restricted trading period for the Distributed Stock.
On April 25, 2023, the Bankruptcy Court entered an order approving the relief requested in the Motion (the “Order”). As set forth in the Order, the Bankruptcy Court extended the Lock-up period for the Distributed Stock until September 1, 2023 (or an otherwise earlier date to be determined, as set forth in the Order). Accordingly, as described in the Order, any shares of the Distributed Stock (including any such shares held by brokerage firms) may not be sold, transferred or otherwise disposed of and the holders of Distributed Stock are prohibited from causing or encouraging any third party to do the same. This extension applies only to the Distributed Stock and does not apply to any securities of Scilex held by Sorrento or any other Scilex securities.
The Company has notified its transfer agent of the Order and the extension of the Lock-up period and, in light of the Order, the restrictive legend on each share of Distributed Stock will be updated to read as follows:
THE SECURITIES REPRESENTED BY THIS CERTIFICATE MAY NOT BE TRANSFERRED, PLEDGED, HYPOTHECATED, LOANED, ENCUMBERED OR OTHERWISE DISPOSED OF WITHOUT THE CONSENT OF SCILEX HOLDING COMPANY (THE “COMPANY”) PRIOR TO SEPTEMBER 1, 2023. A TRANSFER OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE SHALL BE DEEMED TO INCLUDE, WITHOUT LIMITATION, THE (A) SALE OR ASSIGNMENT OF, OFFER TO SELL, CONTRACT OR AGREEMENT TO SELL, GRANT OF ANY OPTION TO PURCHASE OR OTHERWISE DISPOSE OF OR AGREEMENT TO DISPOSE OF, DIRECTLY OR INDIRECTLY, OR ESTABLISHMENT OR INCREASE OF A PUT EQUIVALENT POSITION OR LIQUIDATION WITH RESPECT TO OR DECREASE OF A CALL EQUIVALENT POSITION WITHIN THE MEANING OF SECTION 16 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED (THE “EXCHANGE ACT”), WITH RESPECT TO, ANY SECURITY OF THE COMPANY, (B) ENTRY INTO ANY SWAP OR OTHER ARRANGEMENT THAT TRANSFERS TO ANOTHER, IN WHOLE OR IN PART, ANY OF THE ECONOMIC CONSEQUENCES OF OWNERSHIP OF ANY SECURITY OF THE COMPANY, WHETHER ANY SUCH TRANSACTION IS TO BE SETTLED BY DELIVERY OF SUCH SECURITIES, IN CASH OR OTHERWISE, AND (C) ENGAGEMENT, WHETHER DIRECTLY OR INDIRECTLY, IN ANY (I) “SHORT SALE” (AS SUCH TERM IS DEFINED IN RULE 200 OF REGULATION SHO OF THE EXCHANGE ACT) OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE OR (II) HEDGING TRANSACTION, WHICH ESTABLISHES A NET SHORT POSITION WITH RESPECT TO ANY SECURITIES OF THE COMPANY (INCLUDING THE COMMON STOCK OF THE COMPANY), WITH RESPECT TO EACH OF CLAUSES (I) AND (II) HEREOF, EITHER FOR THE HOLDER’S OWN PRINCIPAL ACCOUNT OR FOR THE PRINCIPAL ACCOUNT OF ANY OTHER PERSON.
Sorrento Therapeutics, Inc. (OTC: SRNEQ, "Sorrento"), a biopharmaceutical company dedicated to the development of life-saving therapeutics to treat cancer, intractable pain, and infectious disease, today announced that, in connection with its ongoing chapter 11 case, the U.S. Bankruptcy Court for the Southern District of Texas entered an order extending the expiration of the restrictions on transfer on the Distributed Stock from May 11, 2023 to September 1, 2023 (or an otherwise earlier date to be determined, as set forth in the order).
https://www.globenewswire.com/news-release/2023/04/25/2654582/0/en/Scilex-Holding-Company-Announces-that-its-Majority-Stockholder-Sorrento-Therapeutics-Inc-has-Issued-a-Notice-that-Sorrento-s-Bankruptcy-Court-has-Extended-the-Lockup-Period-on-Shar.html
They probably will look to sell stock once the PPS is back up into the higher Teens to possible $20’s once the revenue starts flowing in from the deal they recently announced. Will be interesting to see how Q3 and Q4 go.
Thanks for the 411 Stingray! I hope it bounces back up. It really helps to offset the Sorrento bath I have taken so if it gets me back to even (which would be around $20 pps) with SRNE, I will sell to break even between the two…and may consider doing keeping it if the rise is steady and not a spike. Have a GREAT day!
Scilex Holding Shares Tumble Amid Public-Offering Plans
11:59 am ET April 24, 2023 (Dow Jones) Print
By Colin Kellaher
Shares of Scilex Holding Co. fell more than 30% on Monday after the pain-management company said it planned to raise $300 million in a public stock offering.
Scilex shares, which had surged since its majority owner, Sorrento Therapeutics Inc., filed for chapter 11 bankruptcy in February, were recently changing hands at $7.06, down more than 31%.
The Palo Alto, Calif., company, which currently has about 145.8 million shares outstanding, said in a filing with the Securities and Exchange Commission that it plans to use the offering's proceeds for working capital and general corporate purposes, adding that it hasn't designated any specific uses for the funds.
The Wall Street Journal reported earlier this month that Scilex was exploring a sale of new stock to take advantage of the share-price rally.
Yeah, mine are still locked up with TDAmeritrade....I'm not sure that some brokers have not already released them for some people...
Just a guess, because I would have sold at $15 as well....
It’s because of the S1 filing that was filed on Friday 4/21. Market Maker Manipulation in my opinion. The PPS got beat down with very low volume.
I thought nobody could sell until mid May. Otherwise, I would have bailed at $15.
My guess is that some of the brokerages have unlocked the dividend shares and people are selling them...
RESTRICTED SCLX DIVIDEND SHARES
Does ANYONE know if the restricted SCLX dividend shares from SRNE, scheduled to be "unrestricted for sale" on May 12 can be cancelled or postponed by SRNE???
I have 530 dividend shares of SCLX. Many others have even more, and SCLX price is rising now.
What are the parameters for what could happen??
Serious answers only please.
GLTA!!!
Seems like the Market Makers and all the Brokerages who have been holding back giving out the 40+ million dividend shares must have been shorting the stock and now that the Bankruptcy court hearing for SRNEQ came out and said that they all need to report where and what the status of the shares are, should make in my opinion for a very nice continued Short Squeeze.
No love if you can’t sell the dividend that was given to you. I just got off phone with broker. Bisque situation. The shares are restricted.
I love the smell of burnt shorts in the morning, it reminds me of.... Beethoven.
So what’s up with these shares we got from SRNE dividend? When can we sell them?
SQEEEEEEEEEEZZZZZZZZZZZZZZEEEEEEEEEEEEE
Would LUV to see a 200% + squeeze now!!!
I smell a short squeeze now that the Bankruptcy court has informed the Brokerages that they need to follow through and give the entitled shareholders of the dividends their shares so that they can vote accordingly at the annual shareholder meeting. It’s ridiculous that these Brokerages (mine included) are holding back the shares from the account because they say the shares do not have to be given into our accounts until sometime in May….. Total Horse Shit!!!
New 10K
Scilex Holding Company (SCLX) - FORM 10-K | Annual Report https://seekingalpha.com/filing/7316522
https://www.reddit.com/r/BANDOFBROTHERSOFSRNE/comments/11r7wlj/scilex_10k/?utm_source=share&utm_medium=android_app&utm_name=androidcss&utm_term=1&utm_content=share_button
They should have some nice revenue coming in next fiscal year results.
They should have some nice revenue coming in next fiscal year results.
SCLX: News just hit --- exclusive rights to a potent MIGRAINE PAIN drug from one of their (holding) firms. (But then, maybe PAIN, per se, just ain't "TRENDING" these days???)
https://www.globenewswire.com/news-release/2023/02/12/2606303/0/en/Scilex-Holding-Company-a-majority-owned-subsidiary-of-Sorrento-Therapeutics-Inc-acquires-rights-to-FDA-Approved-ELYXYB-in-the-U-S-and-Canada-for-the-acute-treatment-of-migraine.html
//////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////
Sorrento Distributes Dividend Confirmation Statements to 146 Brokerage Firms and Provides Specific Instruction to Continental Stock Transfer & Trust Company Regarding the Dividend of Scilex Holding Company Common Stock
Fri, February 3, 2023 at 5:59 PM PST
Sorrento Therapeutics, Inc.
Sorrento Therapeutics, Inc.
SAN DIEGO, Feb. 03, 2023 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) today distributed dividend confirmation statements to 146 brokerage firms regarding its recent dividend to Sorrento stockholders of shares of common stock of Scilex Holding Company (Nasdaq: SCLX, “Scilex”) held by Sorrento. These statements, which contain the account numbers and amount of Scilex dividend shares, were previously mailed out by Continental Stock Transfer & Trust Company.
The dividend confirmation statements are being distributed on behalf of Sorrento and Scilex to notify each brokerage firm of Sorrento’s previously announced stock dividend (the “Dividend”) consisting of an aggregate of 76,000,000 shares (the “Dividend Stock”) of common stock of Scilex held by Sorrento to record holders of (i) Sorrento’s common stock (the “Record Common Holders”) as of the close of business on January 9, 2023 (the “Record Date”), and (ii) certain warrants to purchase Sorrento common stock (which have or may have the right to participate in the Dividend pursuant to the terms of their respective warrants).
According to Sorrento’s estimates, approximately 60 million or more shares of Sorrento common stock were sold “short” as of the Record Date. In the event the shares of Sorrento common stock were held through a brokerage firm, bank, dealer or other similar organization and were sold “short” as of the Record Date, holders should consult with their financial advisor, broker or other agent immediately to determine whether they may also be deemed “short” Scilex common stock as a result of the Dividend, as well as any obligations required for you to cover your “short” position(s). Please note that “naked short” sales or “naked short” positions in any Sorrento common stock may constitute a violation of the U.S. Securities and Exchange Commission Regulation SHO.
Each Record Common Holder is entitled to receive 0.1410127 of a share of Scilex common stock for each one share of Sorrento common stock held by such Record Common Holder as of the close of business on the Record Date. The payment date for the Dividend was January 19, 2023. The resulting fewer number of shares of Scilex common stock that will be available to trade could cause the trading market of the common stock of Scilex to become less liquid. As noted above, Scilex’s transfer agent, Continental Stock Transfer & Trust Company (“CST”), has already distributed to brokerage firms, as the Record Common Holder (for the benefit of their customers that held Sorrento common stock on the Record Date), a book-entry/DRS transaction confirmation (the “Dividend Confirmation Statement”) reflecting the portion of the Dividend Stock allocated to such firm (for the benefit of their customers that held Sorrento common stock on the Record Date), which Dividend Confirmation Statements were mailed to the addresses on record with The Depository Trust & Clearing Corporation.
In the event that brokerage firms did not receive copies of the Dividend Confirmation Statements, please contact CST immediately. Sorrento and Scilex are requesting that each brokerage firm distribute the Dividend Stock to the actual beneficial owners thereof and to reflect Scilex’s CUSIP number 80880W106 and value of Scilex common stock on each beneficial owner’s brokerage statement.
Sorrento and Scilex have given specific instructions to Scilex’s transfer agent, CST, on how to answer certain inquiries from Record Holders and brokerage firms:
To obtain a copy of the Dividend Confirmation Statement and to have the Dividend Stock reflected on such Dividend Confirmation Statement further distributed to the actual beneficial owners thereof, please contact Scilex’s transfer agent, CST, by phone or email at:
Continental Stock Transfer & Trust Company
Telephone Number: 800-509-5586
Email Address: cstmail@continentalstock.com
Broker List
About Sorrento Therapeutics, Inc.
Sorrento is a clinical and commercial stage biopharmaceutical company developing new therapies to treat cancer, pain (non-opioid treatments), autoimmune disease and COVID-19. Sorrento's multimodal, multipronged approach to fighting cancer is made possible by its extensive immuno-oncology platforms, including key assets such as Abivertinib, next-generation tyrosine kinase inhibitors (“TKIs”), fully human antibodies (“G-MAB™ library”), immuno-cellular therapies (“DAR-T™”), antibody-drug conjugates (“ADCs”), and oncolytic virus (“Seprehvec™”). Sorrento is also developing potential antiviral therapies and vaccines against coronaviruses, including STI-1558, COVI-MSC™; and diagnostic test solutions, including COVIMARK™.
Sorrento's commitment to life-enhancing therapies for patients is also demonstrated by our effort to advance a TRPV1 agonist, non-opioid pain management small molecule, resiniferatoxin (“RTX”), and SP-102 (10 mg, dexamethasone sodium phosphate viscous gel) (SEMDEXA™), a novel, viscous gel formulation of a widely used corticosteroid for epidural injections to treat lumbosacral radicular pain, or sciatica, and to commercialize ZTlido® (lidocaine topical system) 1.8% for the treatment of postherpetic neuralgia (PHN). RTX has been cleared for a Phase II trial for intractable pain associated with cancer and a Phase II trial in osteoarthritis patients. Positive final results from the Phase III Pivotal Trial C.L.E.A.R. Program for SEMDEXA™, its novel, non-opioid product for the treatment of lumbosacral radicular pain (sciatica), were announced in March 2022. ZTlido® was approved by the FDA on February 28, 2018.
For more information visit
Media and Investor Relations
Contact: Brian Cooley
Email:
Sorrento® and the Sorrento logo are registered trademarks of Sorrento Therapeutics, Inc.
G-MAB™, DAR-T™, Seprehvec™, SOFUSA™, COVI-MSC™, COVIMARK™, Ovydso™ and Fujovee™ are trademarks of Sorrento Therapeutics, Inc.
SEMDEXA™ (SP-102) is a trademark of Semnur Pharmaceuticals, Inc. A proprietary name review by the FDA is planned.
ZTlido® is a registered trademark owned by Scilex Pharmaceuticals Inc. All other trademarks are the property of their respective owners.
©2023 Sorrento Therapeutics, Inc. All Rights Reserved.
Looks like today might be the day where there is a major fire in the shorts camp. Hope no one gets burn that doesn't earn it.
Looks like this is going to squeeze big.
Approvals are on the way. I'm sure this board will light up.
Well here it is: a new playground. It will be interesting to see how quickly it fills up.
https://investors.sorrentotherapeutics.com/node/13671/html
https://investors.sorrentotherapeutics.com/node/13676/html
Followers
|
20
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
90
|
Created
|
01/24/23
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |